Steven Boyd, Director, 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 455,000 shares at $1.00 ($451K) on 2022-01-13, disclosed to the SEC on 2022-01-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.04 | 57,300 | $60K | 13.2% |
| 2 | $1.00 | 312,700 | $313K | 69.3% |
| 3 | $0.93 | 85,000 | $79K | 17.5% |
| Total | $0.99 avg | 455,000 | $451K | 100% |
| Filing → |
| CERC | BUY | 2021-08-18 | $194K | — | Filing → |
| EYEG | SELL | 2021-07-29 | $27.9M | — | Filing → |
| RSLS | SELL | 2021-06-22 | $28.5M | — | Filing → |